- Home
- BMBL vs NMRA Comparison
BMBL vs NMRA Comparison
Compare BMBL & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BMBL | NMRA |
|---|---|---|
| Founded | 2014 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 403.6M | 424.4M |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | BMBL | NMRA |
|---|---|---|
| Price | $3.58 | $1.78 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 13 | 8 |
| Target Price | $4.83 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 2.9M | 821.7K |
| Earning Date | 02-17-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,003,141,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.18 | $0.61 |
| 52 Week High | $8.82 | $11.42 |
Technical Indicators
Market Signals| Indicator | BMBL | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 45.08 | 38.77 |
| Support Level | $3.43 | $1.73 |
| Resistance Level | $3.62 | $1.93 |
| Average True Range (ATR) | 0.18 | 0.11 |
| MACD | 0.05 | 0.00 |
| Stochastic Oscillator | 49.53 | 26.14 |
Price Performance
Historical ComparisonAbout BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.